Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

placebo

Placebo Comparator

DRUG

donepezil

Active Comparator

DRUG

ABT-126

low dose, middle dose, high dose

Trial Locations (33)

2196

Site Reference ID/Investigator# 60910, Johannesburg

6529

Site Reference ID/Investigator# 60912, George

7530

Site Reference ID/Investigator# 60911, Belville

7925

Site Reference ID/Investigator# 76073, Cape Town

10312

Site Reference ID/Investigator# 56506, Staten Island

19046

Site Reference ID/Investigator# 82994, Jenkintown

33407

Site Reference ID/Investigator# 56514, West Palm Beach

33445

Site Reference ID/Investigator# 56503, Delray Beach

33613

Site Reference ID/Investigator# 56518, Tampa

36006

Site Reference ID/Investigator# 60905, Poltava

60007

Site Reference ID/Investigator# 62611, Elk Grove Village

76309

Site Reference ID/Investigator# 77636, Wichita Falls

83037

Site Reference ID/Investigator# 60909, Donetsk

119048

Site Reference ID/Investigator# 60951, Moscow

123995

Site Reference ID/Investigator# 60959, Moscow

190020

Site Reference ID/Investigator# 60947, Saint Petersburg

190103

Site Reference ID/Investigator# 60958, Saint Petersburg

192019

Site Reference ID/Investigator# 60949, Saint Petersburg

198510

Site Reference ID/Investigator# 60952, Saint Petersburg

410060

Site Reference ID/Investigator# 60950, Saratov

420012

Site Reference ID/Investigator# 60945, Kazan'

420097

Site Reference ID/Investigator# 60955, Kazan'

610014

Site Reference ID/Investigator# 60954, Kirov

630064

Site Reference ID/Investigator# 60946, Novosibirsk

05201

Site Reference ID/Investigator# 56504, Bennington

81-361

Site Reference ID/Investigator# 62565, Gdynia

61-853

Site Reference ID/Investigator# 62563, Poznan

71-215

Site Reference ID/Investigator# 62562, Szczecin

04112

Site Reference ID/Investigator# 60906, Kiev

BA1 3NG

Site Reference ID/Investigator# 60960, Bath

BB2 3HH

Site Reference ID/Investigator# 60963, Blackburn

G20 0XA

Site Reference ID/Investigator# 60962, Glasgow

TW8 8DS

Site Reference ID/Investigator# 60961, London

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01527916 - Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter